Large randomized clinical trials have proven the efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) in reducing major cardiovascular events, hospitalization for HF, and kidney disease progression.7,8,9 However, the role of SGLT-2is in incident AF remains controversial. The gene discussed is SLC5A2; the disease is atrial fibrillation.